10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics, Inc. (NASDAQ ... webcast of this call will be available on the investor tab of the company's Web site, 10xgenomics.com for at least 45 days following this call.

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Explore 10x Genomics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TXG. Life Science Company 10x Genomics Struggles With Profitability, Analyst Says ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

10x Genomics stands as a pioneer in the life sciences sector, focusing on developing cutting-edge technologies that facilitate high-resolution biological analysis. Its key platforms, including ...

Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, and the ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the ...

Swiss National Bank boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 188,400 ...

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...